GlassScriptPhysician profile
Mark B Kukler
NPI 1093765265
$7,784.87
in general payments reported to CMS, 2019-2025
43 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $802 · 2021: $1,070 · 2022: $1,094 · 2023: $1,211 · 2024: $1,376 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,878.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $610.56 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $344.95 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $306.57 | 2019-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.13 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $296.02 | 2019-2025 | Stelara, Tremfya |
| Lilly USA, LLC | $259.29 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $254.40 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $196.67 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $171.14 | 2021-2022 | |
| Qol Medical, LLC | $161.55 | 2020-2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $160.37 | 2019-2024 | Ocaliva |
| Braintree Laboratories, INC. | $157.47 | 2019-2025 | Suflave, Sutab |
| Ucb, INC. | $151.51 | 2019-2021 | |
| Pfizer INC. | $149.12 | 2019-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kukler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.